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Summary
Growth-promoting signaling molecules, including the
mammalian target of rapamycin complex 1 (mTORC1), drive
the metabolic reprogramming of cancer cells required to
support their biosynthetic needs for rapid growth and prolif-
eration [1]. Glutamine is catabolyzed to a-ketoglutarate
(aKG), a tricarboxylic acid (TCA) cycle intermediate, through
two deamination reactions, the first requiring glutaminase
(GLS) to generate glutamate and the second occurring via
glutamate dehydrogenase (GDH) or transaminases [2]. Acti-
vation of the mTORC1 pathway has been shown previously
to promote the anaplerotic entry of glutamine to the TCA
cycle via GDH. Moreover, mTORC1 activation also stimu-
lates the uptake of glutamine, but the mechanism is
unknown [3]. It is generally thought that rates of glutamine
utilization are limited by mitochondrial uptake via GLS, sug-
gesting that, in addition to GDH, mTORC1 could regulate
GLS. Here we demonstrate that mTORC1 positively regu-
lates GLS and glutamine flux through this enzyme. We
show that mTORC1 controls GLS levels through the S6K1-
dependent regulation of c-Myc (Myc). Molecularly, S6K1
enhances Myc translation efficiency by modulating the
phosphorylation of eukaryotic initiation factor eIF4B, which
is critical to unwind its structured 50 untranslated region
(50UTR). Finally, our data show that the pharmacological in-
hibition of GLS is a promising target in pancreatic cancers
expressing low levels of PTEN.Results and Discussion
The mTORC1 Pathway Regulates GLS1
mTORC1 positively regulates net glutamine flux into the tricar-
boxylic acid (TCA) cycle, therefore suggesting that gluta-
minase (GLS) is potentially regulated by mTORC1 [3]. To test
this possibility, we assessed GLS protein levels in conditions6Co-first author
7Present address: Infinity Pharmaceuticals, 780 Memorial Drive, Cam-
bridge, MA 02139, USA
*Correspondence: job2064@med.cornell.eduof mTORC1 activation. We found that Tsc2 deficiency in
mouse embryonic fibroblasts (MEFs) or the stable expression
of Rheb wild-type (WT) or an active mutant (S16H) resulted in
increased GLS protein levels that were reduced after mTORC1
inhibition (Figures 1A and 1B). Rapamycin potently decreased
GLS levels after 6 hr of treatment (Figure 1C), consistent
with reduced glutamine consumption at the same time point
(Figure 1D). mTOR catalytic inhibitors tested, including
LY294002 andBEZ235, also resulted in decreasedGLS protein
levels in MEFs (Figure 1E). Similar to mTOR inhibitors, the
knockdown of components of the mTORC1 pathway, in-
cluding raptor, Rheb, RagA, and mTOR itself, resulted in
reduced GLS protein levels (Figure S1A available online).
Two different genes in distinct chromosomes code for
mammalian GLS enzymes. The Gls1 gene codes for kidney-
type isozymes, whereas the Gls2 gene encodes liver-type iso-
zymes [4]. Only expression of Gls1, not Gls2, was detected in
our cell system (Figure S1B). In addition, Gls1 mRNA levels
were decreased upon rapamycin treatment in Tsc22/2 MEFs
(Figure S1C). p53 has been shown recently to regulate Gls2
to drive glutamine metabolism. However, no effects on Gls1
have been described [5]. Consistently, the mTORC1-depen-
dent regulation of GLS occurs independently of p53 (Fig-
ure S1D). A modulation of GLS levels by mTORC1 should
also be reflected in the conversion of glutamine to glutamate.
Rapamycin treatment increased the intracellular levels of
glutamine (Figure 1F) [3]. Moreover, mTORC1 inhibition
decreased glutamine flux in Tsc22/2 MEFs expressing an
empty vector (EV) or TSC2 (Figure 1G).
The mTORC1 Pathway Regulates GLS1 via Myc
Oncogenic Myc has been shown to positively stimulate the
expression of genes involved in glutamine metabolism [6].
Moreover, Myc has been shown to regulate GLS by repressing
the transcription of miR-23a/b [7]. Consistent with this, the
effective knockdown of Myc with two siRNAs (#25 and #26)
in the human pancreatic cancer cell line BxPC3 correlated
with reduced GLS protein levels (Figure 2A, lanes 5 and 6).
Similar to GLS, Myc protein levels were dramatically higher
in Tsc22/2 MEFs compared with its WT counterpart and
were sensitive to rapamycin treatment (Figures 1A and 2B).
These observations prompted us to test whether the modula-
tion of GLS levels by mTORC1 occurs via Myc. Strikingly, we
found the stable expression of Myc to abrogate the rapamy-
cin-induced decrease of GLS (Figure 2C).
The mTORC1 Substrate S6K1 Controls Myc and GLS
Although early studies have linked mTORC1 to Myc [8], the
mechanistic details have not been described. We hypothe-
sized that the mTORC1 downstream effector S6 Kinase 1
(S6K1) might modulate Myc. We found that inhibition of S6K1
with PF470861 (PF) or rapamycin resulted in decreased Myc
transcriptional activity (Figure 3A). Moreover, expression of
catalytically active S6K1 (S6K1-F5A/R3A/T389E) [9, 10] re-
sulted in increased levels of both Myc and GLS and prevented
a rapamycin-induced decrease in Myc and GLS levels (Fig-
ure 3B). The rapamycin-resistant S6K1 also significantly re-
duced a rapamycin-induced increase in intracellular glutamine
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Figure 1. The mTORC1 Pathway Regulates GLS1
(A–C and E) GLS protein levels in whole cell lysates from Tsc2 WT and Tsc22/2 MEFs treated with rapamycin (Rapa) for 8 hr (A); HEK293T cells stably ex-
pressing Rheb WT, the mutant S16H Rheb, or EV and treated with rapamycin for 24 hr (B); Tsc22/2 MEFs treated with rapamycin at the indicated time
points (C); and Tsc2 WT and Tsc22/2 MEFs treated with the indicated compounds for 8 hr (E). The concentrations of the compounds were as follows:
rapamycin, 20 ng/ml; LY294002 (LY), 20 mM; and BEZ235, 10 mM.
(D) Time course of glutamine consumption in Tsc22/2 MEFs incubated with or without 20ng/ml rapamycin for 24 hr. Each time data point is an average of
triplicate experiments.
(F) Intracellular glutamine levels in Tsc22/2 MEFs treated with rapamycin for 24 hr.
(G) Glutamine flux in Tsc22/2MEFs expressing an EV or re-expressing TSC2 treatedwith the indicated compounds for 24 hr. The concentrations of the com-
pounds were as follows: rapamycin 20 ng/ml; LY294002, 20 mM; BEZ235, 10 mM; BPTES, 10 mM; and 6-diazo-5-oxo-l-norleucine, 1mM.
The mean is shown. Error bars represent the SEM from at least three biological replicates. Numbers below the immunoblot image represent quantification
normalized to the loading control. See also Figure S1.
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treatment with PF led to reduced levels of Myc and GLS (Fig-
ures S2A and S2B). PF treatment or S6K1/2 knockdown
increased intracellular glutamine levels (Figure3D;FigureS2C),
which correlated with decreased glutamine uptake rates in
S6K1/2-depleted cells (Figure 3E). Importantly, knockdown
of Myc resulted in increased intracellular levels of glutamine
that were comparable to those observed in cells after S6K in-
hibition (Figures S2D and S2E). Collectively, these show the
biological significance of the S6K1/Myc-mediated regulation
of GLS and glutamine metabolism.Myc Is Regulated by S6K1 through eIF4B
Rapamycin treatment represses translation ofMycmRNA [11],
which contains a secondary structure in its 50 untranslated re-
gion (50UTR) [12]. Consistent with this, treatment with the
translation inhibitor cycloheximide decreased the Myc protein
level, which was comparable with rapamycin treatment for
24 hr (Figure S3A). S6K1 promotes the translation of mRNAs
with highly structured 50UTRs [13], suggesting a potential
regulation ofMycmRNA translation. To assess this possibility,
we used a luciferase reporter containing the sequence of the
50UTR of Myc. We found rapamycin and PF to significantly
A B C Figure 2. ThemTORC1Pathway RegulatesGLS1
via Myc
GLS and Myc protein levels in whole cell lysates
fromBxPC3 cells transfected with a nontargeting
control (NTC) siRNA or four independent siRNAs
against Myc for 72 hr (A), Tsc2 WT and Tsc22/2
MEFs treated with rapamycin (20 ng/ml) for 8 hr
(B), and Tsc22/2 MEFs stably expressing Myc
or EV and treated with rapamycin (20 ng/ml) for
24 hr (C).
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luciferase mRNA levels were not affected (Figure 3F; Fig-
ure S3B). Rapamycin induced endogenousMycmRNA to shift
toward lighter polysomal fractions (Figure 3G; [14]), demon-
strating that Myc translation is decreased in conditions of
mTORC1 inhibition. In contrast, distribution of GLS and Actin
mRNAs, which do not contain highly structured 50UTRs, were
not affected by rapamycin treatment (Figure 3G).
S6K1-dependent phosphorylation of eIF4B on S422 re-
sults in increased association of eIF4B to eIF4A within the
translation preinitiation complex (PIC) [15] and subsequent
enhancement of eIF4A helicase activity [16]. Importantly,
the knockdown of either eIF4B or eIF4A resulted in reduced
levels of GLS and Myc (Figure 3H; Figure S3C). Consistently,
upon overexpression of eIF4B, Myc mRNA moved toward
heavier polysomal fractions, whereas knockdown of eIF4B
resulted in a Myc mRNA presence in lighter polysomal frac-
tions (Figure S3D; [17]). To further evaluate the implication
of S6K1/eIF4B on Myc, we used a phosphomimetic mutant
of eIF4B (S422D). Strikingly, the mutation of this residue
suppressed the rapamycin-induced decrease of GLS and
Myc (Figure 3I).
Inhibition ofGLSReduces theGrowth of Pancreatic Cancer
Cells
Recent studies have demonstrated a major role for glutamine
in supporting cancer cell metabolism, suggesting that the
mTORC1-dependent regulation of GLS may be relevant for
cancer cells. We measured GLS and Myc levels in three
pancreatic cancer tumor cell lines, BxPC3, MIAPaCa-2, and
AsPC-1. Both BxPC3 and MIAPaCa-2 cells displayed a higher
basal phosphorylation of S6 (Figure 4A), consistent with lower
levels of PTEN [18]. Levels of both GLS andMyc were higher in
BxPC3 andMIAPaCa-2 cells andwere reduced uponmTORC1
inhibition with rapamycin or BEZ235 treatment (Figure 4A).
Interestingly, BEZ235 effects on GLS were more pronounced
in BxPC3 cells (Figure 4A). Higher GLS levels correlated with
increased glutamine consumption in BxPC3 cells compared
with AsPC-1 cells (Figure 4B). Given the importance of gluta-
mine metabolism in driving the growth of cancer cells, we
speculated that the inhibition of glutamine metabolism might
reduce the growth of pancreatic cells with increased mTORC1
signaling. To test this idea, we used the GLS-1 inhibitor
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3
(BPTES) in an anchorage-independent growth assay. We
found BPTES to significantly reduce the ability of BxPC3 cells
to grow in soft agar but not to affect the growth of AsPc-1 cells
(Figures 4C and 4D). The growth of pancreatic ductal adeno-
carcinoma has been shown recently to be sensitive to GLS-1
inhibition [19]. The addition of the TCA cycle intermediate
oxaloacetate (OAA) was able to rescue BxPC3 cell growth
upon GLS inhibition (Figure 4C). OAA has been shown toplay an important role in pancreatic cancer cell growth by
maintaining the reduced formof nicotinamide adenine dinucle-
otide phosphate (NADPH)/ nicotinamide adenine dinucleotide
phosphate (NADP+) ratio [19]. Consistently, we observed that
the antioxidant N-acetylcysteine (NAC) rescued the decreased
growth of BxPC3 cells cultured in the presence of BPTES (Fig-
ure 4D). Together, these data indicate that the mTORC1-medi-
ated regulation of GLS is critical for glutamine anaplerosis,
redox homeostasis, and pancreatic cancer cell growth.
In this study, we identified GLS as a downstream effector of
mTORC1/S6K1 signaling involved in energy metabolism. We
demonstrated that S6K1 positively controls GLS by increasing
the translation efficiency of the oncogene Myc mRNA. Molec-
ularly, we showed that S6K1 regulates Myc by phosphory-
lating the initiation factor eIF4B (Figure 3). Our data extend
our earlier model demonstrating that the phosphorylation of
eIF4B promotes the association of eIF4B to eIF4A in the PIC
[15]. This interaction enhances eIF4A helicase activity and
Myc mRNA translation as a result of improving the ability
of the PIC to transit to the translation start site and/or by
exposing a possible internal ribosome entry site hidden within
the structured 50UTR [20, 21]. In this way, mTORC1/S6K1-
regulated helicase stimulation is increasing the number of
ribosomes engaged in Myc mRNA translation. Consistently,
changes in Myc mRNA distribution, from heavier to lighter
polysomes, by rapamycin or by eIF4B knockdown, were
observed and are consistent with previous polysome profiles
(Figure 3G; Figure S3D) [14, 17]. Although S6K1-mediated
regulation of Myc protein stability has also been suggested
[22, 23], we did not see a significant change in Myc level with
MG132 treatment under the conditions used in our analysis
(Figure S3E). In addition, exogenous Myc, which does not
have the 50UTR, was not decreased significantly by rapamycin
(Figure 2C) compared with endogenous Myc with its 50UTR
(Figure 2B). Collectively, these data are consistent with the
model that mTORC1/S6K1 controls Myc expression by modu-
lating its mRNA translation initiation efficiency.
Previous studies have demonstrated that oncogenic Myc
positively regulates GLS levels posttranscriptionally by re-
pressing miR-23a/b expression [7]. Importantly, inhibition of
mTORC1 by rapamycin increased miR-23a/b levels (Fig-
ure S3F), linking mTORC1 regulation of GLS expression
through Myc-mediated miR-23a/b control. Interestingly, we
observed the regulation of GLS expression by mTORC1/
S6K1 both at the protein and mRNA levels. However, Gls tran-
scription was not significantly affected by Myc knockdown
(Figure S3G), which is consistent with previous work showing
that Gls mRNA levels do not respond to alterations in Myc
levels in P493-6 cells [7]. Therefore, although the Myc-medi-
ated control of GLS expression plays a major role downstream
ofmTORC1,mTORC1may have othermechanisms to regulate
Gls mRNA levels.
A B C D
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Figure 3. The mTORC1 Substrate S6K1 Controls GLS through Myc mRNA Translation
(A) Normalized luciferase light units of Tsc22/2 MEFs stably expressing a Myc-responsive firefly luciferase construct (Myc-Luc) or vector control (pCignal
Lenti-TRE Reporter). Myc transcriptional activity was measured after treatment with rapamycin (20 ng/ml) or PF4708671 (10 mM) for 8 hr.
(B) GLS and Myc protein levels in whole cell lysates from HEK293T cells expressing HA-S6K1-CA (F5A-R3A-T389E) or EV treated with rapamycin (20 ng/ml)
for 24 hr. HA, hemagglutinin.
(C and D) Intracellular glutamine levels of Tsc22/2MEFs stably expressing S6K-CA (F5A/R5A/T389E,mutating either the three arginines or all residues within
the RSPRR motif to alanines shows the same effect; [10]) or empty vector and treated with rapamycin (20 ng/ml) or DMSO for 48 hr (C) or transfected with
NTC siRNA or siRNA against both S6K1/2 (D). 24 hr posttransfection, cells transfected with NTC siRNA were treated with PF4708671 (10 mM) or DMSO
for 48 hr.
(E) Glutamine consumption of Tsc22/2MEFs transfected with NTC siRNA or siRNA against both S6K1/2. 72 hr posttransfection, media were collected, and
levels of glutamine in the media were determined.
(legend continued on next page)
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Figure 4. Inhibition of GLS Reduces the Growth
of Pancreatic Cancer Cells
(A) GLS and Myc protein levels in whole cell
lysates from BxPC3, MIAPaCa-2, or AsPC-1 cells
treated with rapamycin (20 ng/ml) or BEZ235
(1 mM) for 24 hr.
(B) Glutamine consumption of BxPC3 or AsPC-1
cells 48 hr after plating.
(C and D) Soft agar assays with BxPC3 or AsPC-1
cells treated with BPTES (10 mM), the combina-
tion of BPTES (10 mM) + OAA (2 mM) (C) and
BxPC3 or AsPC-1 cells treated with BPTES,
and the combination of BPTES (10 mM) + NAC
(10 mM) (D). NS, not significant.
Themean is shown. Error bars represent the SEM
from at least three biological replicates.
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2278Through the regulation of GLS, S6K1 is directly linked, for the
first time, to glutamine uptake and metabolism. Interestingly,
two recent studies demonstrated that S6K1 controls the syn-
thesis of nucleotides [24, 25], a process that requires gluta-
mine-derived nitrogen. Therefore, the combination of these
studies and the data presented here reveal the existence of a
positive feedback mechanism through which mTORC1/S6K1
signaling promotes glutamine uptake via GLS, providing build-
ing blocks to create the genetic material required for cell
growth. Besides providing nitrogen for protein and nucleotide
synthesis, glutamine serves as fuel for growth and proliferation
[26]. Interestingly,mTORC1alsostimulates anaplerotic entryof
glutamine-derived a-ketoglutarate to the TCA cycle via gluta-
mate dehydrogenase [3], demonstrating that the activation of
mTORC1 is involved in every aspect of glutamine anaplerosis.
Increasing evidence supports a major role of glutamine
metabolism in driving tumor growth. For example, the knock-
down or inhibition of GLS impairs growth of multiple cancer
cells, including prostate, glioma, lymphoma, and pancreatic
cancer cells [7, 19, 27, 28]. Along these lines, we observed
reduced anchorage-independent growth of pancreatic tumor
cells expressing higher levels of GLS as a result of mTORC1(F) Normalized luciferase light units of Tsc2WTMEFs transfected with the pDL-N reporter construct contai
luciferase. Firefly luciferasewas used as an internal control. 48 hr posttransfection, cells were treatedwith r
(G) Relative levels ofMyc,Gls, andActinmRNA in each polysomal gradient fraction. mRNA levels were mea
5S rRNA level. HEK293T cells were treated with rapamycin (20 ng/ml) for 24 hr, and polysomes were fract
are averaged from two independent experiments performed in duplicate, and the error bars denote SEM
(H and I) GLS andMyc protein levels in whole cell lysates from Tsc22/2MEFs transfected with NTC siRNA o
(H) and Tsc22/2 MEFs stably expressing eIF4B WT, mutant S422D, or EV) and treated with rapamycin fo
The mean is shown. Error bars represent the SEM from at least three biological replicates. The asterisk den
immunoblot image represent quantification normalized to the loading control. See also Figures S2 and Shyperactivation upon GLS-1 inhibition
with BPTES. This finding may have sig-
nificant therapeutic implications, given
that clinical-grade GLS inhibitors are
being developed [29] and because
increased glutamine metabolism is not
critical for normally differentiated cells.
The use of GLS inhibitors may provide
greater efficacy with fewer and less
toxic side effects.
Experimental Procedures
Cell Lines and Culture
Tsc22/2 p532/2, Tsc2 WT p532/2, Tsc12/2
p532/2, and Tsc12/2 p53+/+ MEFs wereprovided by Drs. Brendan Manning and David Kwiatkowski (Harvard
Medical School). All the other cell lines (HT-29, BxPC3, MIAPaCa-2,
AsPC-1, and HEK293T) were obtained from the ATCC. MEFs, HT-29,
and HEK293T cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM). BxPC3, MIAPaCa-2, and AsPC-1 cells were cultured
in RPMI medium (Mediatech). DMEM or RPMI medium were supple-
mented with 10% fetal bovine serum (FBS) (dialyzed for deprivation ex-
periments, Gibco). All extra energetic additives that are often added to
some DMEM formulations, such as sodium pyruvate and succinate,
were excluded.
Cell Lysis and Immunoblotting
Cells washed once with cold PBS were solubilized on ice either in a regular
lysis buffer (40 mM HEPES [pH 7.4], 1 mM EDTA, 120 mM NaCl, 10 mM
b-glycerophosphate, 1 mM NaF, 1 mM Na3VO4, and 0.3% 3-([3-cholamido-
propyl)dimethylammonio)-1-propanesulfonate (CHAPS) or in a low-salt
lysis buffer (40 mM HEPES [pH 7.4], 1 mM EDTA, 10 mM b-glycerophos-
phate, 1 mM NaF, 1 mM Na3VO4, and 0.3% CHAPS) supplemented with
protease inhibitors (250 mMPMSF, 5 mg/ml Pepstatin A, 10 mg/ml Leupeptin,
and 5 mg/ml Aprotinin). Cleared cell lysates were obtained by centrifugation
at 10,000 rpm for 10 min at 4C, and 30 mg of the lysates was used
for immunoblotting. In brief, proteins were resolved by 8%–12% SDS-
PAGE, followed by transfer onto a nitrocellulose membrane. Primary
antibodies were incubated overnight at 4C. Infrared fluorescent IRDye sec-
ondary antibodies were used to develop band intensities in the LI-CORning the 50UTR of Myc under the control ofRenilla
apamycin (20 ng/ml) or PF4708671 (10 mM) for 8 h.
sured by quantitative PCR and normalized to the
ionated on sucrose density gradients. The values
(n = 4).
r two independent siRNAs against eIF4B for 72 hr
r 24 hr (I).
otes a nonspecific band. The numbers below the
3.
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2279Biosciences/Odyssey system. Band intensities were quantified using
Adobe Photoshop CS3 extended software.
Glutamine Consumption and Glutamine Flux
Glutamine concentrations were measured in fresh and spent medium (after
24–48 hr of culture in the presence or absence of drugs) using a Yellow
Springs Instruments 7100. Glutamine levels were normalized to cell number.
The media used for these experiments did not contain pyruvate and were
supplemented with 10% dialyzed FBS. Net glutamine flux was calculated
from glutamine uptake rates and glutamate secretion rates.
Statistics
Data were expressed as average 6 SEM of at least three independent
experiments performed in triplicates. An unpaired, two-tailed Student’s
t test was used to determine differences between two groups.
Supplemental Information
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.cub.2014.08.007.
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